IMU 4.00% 4.8¢ imugene limited

Allogene is starting a trial in first line treatment for LBCL....

  1. 577 Posts.
    lightbulb Created with Sketch. 127
    Allogene is starting a trial in first line treatment for LBCL. Interesting reading their pipeline, seems they are strong competition to IMU, but hey it’s a massive market so many companies in this space will thrive ?
 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.